{"id":"epirubicin-hydrochloride-for-injection","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"60-90","effect":"Alopecia"},{"rate":"10-30","effect":"Mucositis"},{"rate":"1-5","effect":"Cardiotoxicity (dose-dependent)"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"30-50","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epirubicin is an anthracycline chemotherapy agent that inserts itself between DNA base pairs and blocks topoisomerase II-mediated DNA repair, causing double-strand breaks and apoptosis. It is particularly effective against rapidly proliferating cells in solid tumors and hematologic malignancies. The hydrochloride salt formulation is administered intravenously for systemic distribution.","oneSentence":"Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:12.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and metastatic)"},{"name":"Gastric cancer"},{"name":"Lymphomas"},{"name":"Other solid tumors as part of combination chemotherapy regimens"}]},"trialDetails":[{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":"TNBC","enrollment":43},{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT06513364","phase":"PHASE1","title":"Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Beijing Wehand-Bio Pharmaceutical Co., Ltd","startDate":"2024-09-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT07197697","phase":"PHASE2","title":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT01630083","phase":"PHASE2","title":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-19","conditions":"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma","enrollment":252},{"nctId":"NCT03314805","phase":"PHASE2","title":"PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"PhytoHealth Corporation","startDate":"2018-03-01","conditions":"Cancer-related Fatigue, Neutropenia, Malignant","enrollment":67},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT06766266","phase":"PHASE1","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-01-10","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT06848556","phase":"PHASE1, PHASE2","title":"Evaluate the Effect of Tirazamine on Primary Liver Cancer.","status":"TERMINATED","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2021-05-14","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":16},{"nctId":"NCT06671262","phase":"PHASE2","title":"Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-12-26","conditions":"Breast Adenocarcinoma","enrollment":74},{"nctId":"NCT06705127","phase":"PHASE2","title":"Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-01","conditions":"HR-positive,HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT04220944","phase":"PHASE1","title":"Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-01-01","conditions":"Hepatic Carcinoma","enrollment":45},{"nctId":"NCT06441110","phase":"PHASE3","title":"Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-06-01","conditions":"Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active","enrollment":76},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT06371807","phase":"PHASE2","title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Fundacao Champalimaud","startDate":"2024-07","conditions":"Early Breast Cancer, Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT06309732","phase":"PHASE2","title":"GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2006-07","conditions":"Testicular Neoplasms","enrollment":36},{"nctId":"NCT01822314","phase":"PHASE3","title":"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2013-04","conditions":"Breast Cancer","enrollment":632},{"nctId":"NCT02527746","phase":"PHASE1","title":"Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2012-12","conditions":"Neutropenia, Breast Cancer","enrollment":18},{"nctId":"NCT06227065","phase":"PHASE2","title":"Precise Neoadjuvant Chemoresection of Low Grade NMIBC","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2024-10","conditions":"Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk","enrollment":28},{"nctId":"NCT05975151","phase":"PHASE2","title":"Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Bladder Cancer","enrollment":63},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412},{"nctId":"NCT04433156","phase":"PHASE2","title":"VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-04-22","conditions":"Marginal Zone Lymphoma","enrollment":60},{"nctId":"NCT05681728","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-02-01","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT05678933","phase":"PHASE3","title":"AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Peripheral T-cell Lymphoma Targeted Therapy","enrollment":200},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT05204524","phase":"NA","title":"Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-08-27","conditions":"Leiomyosarcoma","enrollment":28},{"nctId":"NCT04059003","phase":"","title":"CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2019-11-01","conditions":"Breast Neoplasms","enrollment":200},{"nctId":"NCT02535221","phase":"PHASE3","title":"Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer","status":"RECRUITING","sponsor":"Peking University","startDate":"2015-07-29","conditions":"Breast Cancer","enrollment":234},{"nctId":"NCT02468739","phase":"PHASE3","title":"Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Breast Cancer","enrollment":206},{"nctId":"NCT05017922","phase":"NA","title":"Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma, Esophagogastric Varices","enrollment":89},{"nctId":"NCT05053386","phase":"NA","title":"Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10","conditions":"Hepatocellular Carcinoma","enrollment":186},{"nctId":"NCT04067102","phase":"NA","title":"Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC","status":"WITHDRAWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-05-10","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55},{"nctId":"NCT04031703","phase":"PHASE3","title":"Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Breast Cancer","enrollment":647},{"nctId":"NCT03785704","phase":"PHASE2","title":"Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2019-01-01","conditions":"Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity","enrollment":60},{"nctId":"NCT04213898","phase":"PHASE1, PHASE2","title":"SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-01","conditions":"Triple-negative Breast Cancer","enrollment":39},{"nctId":"NCT03251768","phase":"PHASE2","title":"Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-10-19","conditions":"Chemotherapy-induced Neutropenia","enrollment":80},{"nctId":"NCT03815474","phase":"PHASE2","title":"Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2019-05-20","conditions":"Sarcoma, Soft Tissue","enrollment":47},{"nctId":"NCT01386346","phase":"PHASE1","title":"Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2011-06","conditions":"Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach","enrollment":12},{"nctId":"NCT01190345","phase":"PHASE2","title":"Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2010-05","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT02521441","phase":"PHASE2","title":"A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2014-07-03","conditions":"Neutropenia","enrollment":138},{"nctId":"NCT00950300","phase":"PHASE3","title":"A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-16","conditions":"Breast Cancer","enrollment":596},{"nctId":"NCT03373708","phase":"PHASE2, PHASE3","title":"Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-12-20","conditions":"Breast Cancer, Chemotherapy, Endocrine Breast Diseases","enrollment":200},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT02980965","phase":"PHASE3","title":"Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2013-05","conditions":"Breast Cancer Female","enrollment":249},{"nctId":"NCT00722293","phase":"PHASE1","title":"A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-08","conditions":"Neoplasms, Breast","enrollment":111},{"nctId":"NCT03314532","phase":"NA","title":"The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-11-01","conditions":"Surgical Resection, HCC","enrollment":230},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT02465801","phase":"PHASE2","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2014-12-16","conditions":"Chemotherapy-induced Neutropenia","enrollment":216},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT01503905","phase":"NA","title":"Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2011-12","conditions":"Breast Cancer Nos Premenopausal","enrollment":600},{"nctId":"NCT02638857","phase":"PHASE1, PHASE2","title":"Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2015-09","conditions":"Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT02119715","phase":"PHASE2","title":"A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2011-02","conditions":"Breast Cancer, Neutropenia, Febrile Neutropenia","enrollment":182},{"nctId":"NCT00054587","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2001-06","conditions":"Breast Cancer","enrollment":3010},{"nctId":"NCT00123318","phase":"PHASE3","title":"A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-02","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT01428414","phase":"PHASE2","title":"Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhimin Shao","startDate":"2011-08","conditions":"HER-2 Positive Breast Cancer","enrollment":100},{"nctId":"NCT00286819","phase":"PHASE2","title":"Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer","status":"COMPLETED","sponsor":"Central European Cooperative Oncology Group","startDate":"2005-04","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT00518557","phase":"NA","title":"Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis","status":"UNKNOWN","sponsor":"Southeast University, China","startDate":"2007-04","conditions":"Hepatocellular Carcinoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epirubicin Hydrochloride for Injection","genericName":"Epirubicin Hydrochloride for Injection","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells. Used for Breast cancer (adjuvant and metastatic), Gastric cancer, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}